Tanabe Pharma Corporation

Quick facts

Marketed products

• alpha-glucosidase inhibitor · Diabetes
  Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes.
• Canagliflozin (TA-7284) · Diabetes
  Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.
• GLP-1 analogue
• Iron supplement A · Hematology
  Iron supplement A provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis.
• Iron supplement C · Hematology
  Iron supplement C replenishes iron stores to treat or prevent iron deficiency anemia by providing bioavailable iron for hemoglobin synthesis.
• Sodium Ozagrel · Cardiovascular
  Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis.
• Teneli (Teneligliptin) · Diabetes
  Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

Phase 3 pipeline

• DPT-IPV · Immunology / Infectious Disease
  DPT-IPV is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, and inactivated poliovirus.
• DPT-IPV-Hib · Immunology / Infectious Disease Prevention
  DPT-IPV-Hib is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b through inactivated pathogen antigens and toxoids.
• DPT-IPV-Hib (Combined Vaccine) · Immunology / Infectious Disease Prevention
  This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.
• DPT-IPV-Hib-High（Combined Vaccine） · Immunology / Infectious Disease
  This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.
• DPT-IPV-Hib-Low（Combined Vaccine） · Immunology / Infectious Disease Prevention
  This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b pathogens.
• glinide · Other
• IFN beta(24 weeks) · Immunology
  Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.
• IFN beta(48 weeks) · Immunology
  Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.
• Iron supplement B · Hematology
  Iron supplement B replenishes iron stores to treat or prevent iron deficiency anemia by restoring hemoglobin production.
• Iron supplement D · Hematology
  Iron supplement D replenishes iron stores to treat or prevent iron deficiency anemia.
• MCI-186 · Neurology
  MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue.
• MCI-186 in open label phase · Neuroprotection
  MCI-186 is a free radical scavenger.
• MCI-196 · Nephrology / Chronic Kidney Disease
  MCI-196 is a phosphate binder that reduces serum phosphate levels by binding phosphate in the gastrointestinal tract.
• MCI-9042 · Neurology
  MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein.
• MP-424 · Virology/Hepatology
  MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.
• MP-513 · Immunology
  MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
• MT-6548 · Musculoskeletal / Endocrinology
  MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues.
• Placebo of MCI-186 · Neurology
  This is a placebo control arm and contains no active pharmaceutical ingredient.
• Placebo of MCI-196
  This is a placebo control arm and contains no active pharmaceutical ingredient.
• Placebo of MP-513
  This is a placebo control and contains no active pharmaceutical ingredient.
• Placebo of Simvastatin · Cardiovascular
  This is a placebo control formulation used in clinical trials to compare against the active simvastatin drug and has no therapeutic mechanism.
• RBV(24 weeks) · Infectious Disease
  Ritonavir is a protease inhibitor used to treat HIV/AIDS by preventing the replication of the virus.
• RBV(48 weeks) · Infectious Diseases
  Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.
• TA-650 · Diabetes
  TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• TA-7284 High · Cardiovascular
  TA-7284 High is a drug that targets the renin-angiotensin system.
• TA-7284 Low · Diabetes
  TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion.
• TAU-284 · Neurology
  Tau-284 is a tau aggregation inhibitor.
• Teneli / Teneli + pio · Diabetes
  Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals, improving glycemic control in type 2 diabetes.
• Teneli / Teneli + SU · Diabetes
  Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals.
• Teneligliptin/Canagliflozin · Diabetes
  Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
• Teneligliptin + Sulfonylurea · Diabetes
  Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while the sulfonylurea component stimulates pancreatic beta cells to release insulin.

Phase 2 pipeline

• MCC-257
• MP-214
• MP-513 High Dose and Metformin
• MP-513 Low Dose and Metformin
• MP-513 Lowest Dose and Metformin
• MP-513 Medium Dose and Metformin
• MT-1303-High
• MT-1303-Low
• MT-1303-Middle
• MT-2990
• MT-3921
• MT-3995 High
• MT-3995 Low
• MT-3995 Middle
• MT-5199
• MT-5547
• MT-8554
• MT-8554 high dose
• MT-8554 low dose
• MT-8554 middle dose
• TA-7284-High-middle
• TA-7284-Low-middle

Phase 1 pipeline

• MT-1303-FormA
• MT-1303-FormB
• MT-1303 High dose
• MT-1303 Low dose
• MT-2111
• MT-3534
• MT-4129
• MT-5625 high dose
• MT-5625 low dose
• MT-5625 middle dose
• TA-7284

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tanabe Pharma Corporation portfolio CI brief
• Tanabe Pharma Corporation pipeline updates RSS